Literature DB >> 1365416

A68930: a potent agonist specific for the dopamine D1 receptor.

J W Kebabian1, M P DeNinno, R Schoenleber, R MacKenzie, D R Britton, K E Asin.   

Abstract

A68930, [1R, 3S] 1-aminomethyl-5,6-dihydroxy-3-phenylisochroman HCl, is a potent, partial agonist in the dopamine-sensitive adenylate cyclase model of the D1 dopamine receptor in fish retina. In the rat caudate-putamen model of the D1 dopamine receptor, A68930 is a potent (EC50 2.1 nM) full agonist. In contrast, A68930 is a much weaker (EC50 = 3,920 nM) full agonist in a biochemical model of the D2 dopamine receptor. A68930 also displays weak 2 agonist activity but the molecule is virtually inactive at the 1 and beta-adrenoceptors. When tested in rats bearing a unilateral 6-OHDA lesion of the nigro-neostriatal neurons, A68930 elicits prolonged (> 20 hr) contralateral turning.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365416     DOI: 10.1016/0197-0186(92)90230-o

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  4 in total

1.  Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.

Authors:  Tina Scardochio; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

Review 2.  The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413.

Authors:  Yvonne Connolly Martin
Journal:  Int J Med Chem       Date:  2011-03-24

3.  The dopamine D1 receptor is expressed and facilitates relaxation in airway smooth muscle.

Authors:  Kentaro Mizuta; Yi Zhang; Dingbang Xu; Fumiko Mizuta; Frank D'Ovidio; Eiji Masaki; Charles W Emala
Journal:  Respir Res       Date:  2013-09-02

4.  The Signaling and Pharmacology of the Dopamine D1 Receptor.

Authors:  Jace Jones-Tabah; Hanan Mohammad; Emma G Paulus; Paul B S Clarke; Terence E Hébert
Journal:  Front Cell Neurosci       Date:  2022-01-17       Impact factor: 5.505

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.